Research from the TB-HIV Treatment group was recently published in Clinical Infectious Disease. Sivro et al. describe immune correlates of TB recurrence in a co-hort of HIV–infected individuals on antiretroviral therapy with a history of prior TB cure.
The study included a subset of participants from the CAPRISA 005 TB Recurrence upon Treatment with HAART (TRuTH) cohort based at the CAPRISA eThekwini clinic in Durban, South Africa. Selection of 23 different soluble immune markers were measured in plasma samples from 63 cases (patients with recurring TB) and 123 controls (patients with no evidence of recurring TB).
Pro-inflammatory cytokines, Inter-leukin 6 (IL6), interleukin 1b (IL1b) and interleukin 1Ra (IL1Ra) were as-sociated with increased risk of TB re-currence while Type I interferon, IFNb was associated with decreased TB risk (Figure). Longitudinal analysis of samples during active TB and follow-ing successful TB treatment identified several markers of active disease and TB treatment response (IL6, IP10, sCD14 and IFNg).
Sivro et al. wrote: “Because all HIV -infected individuals now qualify for ART, but ART does not completely ameliorate HIV-associated TB risk, the population for this study is im-portant for defining TB risk factors.”
For further reading see:
Sivro A et al. Plasma Cytokine Predictors of Tuberculosis Recurrence in Antiretroviral-Treated HIV-infected Individuals from Durban, South Africa. Clinical Infectious Diseases 2017; 65(5): 819-826.
Share this articleBack